T·Time starts cash-pay compounded GLP-1 and GIP injections at flat pricing
The telehealth seller is pricing compounded incretin injections on a flat cash-pay basis rather than through insurance.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 9 05:28 ETSource: StreetInsider
The wire
- 01T·Time announced a cash-pay service offering compounded GLP-1 and GIP injections under a flat pricing model, according to the company's announcement.
- 02Compounded incretin offerings remain a live question for pharmacists and telehealth operators after FDA ended the semaglutide and tirzepatide shortage listings.
- 03The release is company-issued; sourcing of the active ingredients, prescriber model and compliance with 503A rules are not detailed.
From the source
Read at streetinsider.comT·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing
